BioCatalystWatch
CABAWorkspace / CABA / OverviewCompany library
Price
Market cap
Next catalyst2H26rese-cel (CABA-201) · Data readoutCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

rese-cel (CABA-201)

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

rese-cel (CABA-201)

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

rese-cel (CABA-201)

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

rese-cel (CABA-201)

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Other pipelines

rese-cel (CABA-201)

CD19

History / paused

Anti-MuSK B-cell receptor

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

CABA SEC archive